

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
7.0	24.03.2025	1228554-00023	Date of first issue: 18.01.2017

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Abamectin Liquid Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-
stance/Mixture : Veterinary product

Recommended restrictions
on use : Not applicable

1.3 Details of the supplier of the safety data sheet

Company : MSD
Kilsheelan
Clonmel Tipperary, IE

Telephone : 353-51-601000

E-mail address of person
responsible for the SDS : EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

+1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Acute toxicity, Category 4	H332: Harmful if inhaled.
Specific target organ toxicity - repeated exposure, Category 2	H373: May cause damage to organs through prolonged or repeated exposure.
Short-term (acute) aquatic hazard, Category 1	H400: Very toxic to aquatic life.
Long-term (chronic) aquatic hazard, Category 1	H410: Very toxic to aquatic life with long lasting effects.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms :



SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
7.0	24.03.2025	1228554-00023	Date of first issue: 18.01.2017

Signal word : Warning

Hazard statements : H332 Harmful if inhaled.
H373 May cause damage to organs through prolonged or repeated exposure.
H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements : **Prevention:**
P271 Use only outdoors or in a well-ventilated area.
P273 Avoid release to the environment.

Response:
P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/ doctor if you feel unwell.
P314 Get medical advice/ attention if you feel unwell.
P391 Collect spillage.

Hazardous components which must be listed on the label:
abamectin (combination of avermectin B1a and avermectin B1b) (ISO)

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
abamectin (combination of avermectin B1a and avermectin B1b) (ISO)	71751-41-2 606-143-00-0	Acute Tox. 2; H300 Acute Tox. 1; H330 Acute Tox. 3; H311 Repr. 2; H361fd STOT RE 1; H372 (Central nervous)	>= 1 - < 2,5

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Abamectin Liquid Formulation

Version 7.0	Revision Date: 24.03.2025	SDS Number: 1228554-00023	Date of last issue: 28.09.2024 Date of first issue: 18.01.2017
----------------	------------------------------	------------------------------	---

		system) Aquatic Acute 1; H400 Aquatic Chronic 1; H410 M-Factor (Acute aquatic toxicity): 10.000 M-Factor (Chronic aquatic toxicity): 10.000 specific concentra- tion limit STOT RE 1; H372 >= 5 % STOT RE 2; H373 0,5 - < 5 %	
--	--	---	--

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

- | | |
|----------------------------|---|
| General advice | : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice. |
| Protection of first-aiders | : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8). |
| If inhaled | : If inhaled, remove to fresh air.
If not breathing, give artificial respiration.
If breathing is difficult, give oxygen.
Get medical attention. |
| In case of skin contact | : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse. |
| In case of eye contact | : Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists. |
| If swallowed | : If swallowed, DO NOT induce vomiting. |

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
7.0	24.03.2025	1228554-00023	Date of first issue: 18.01.2017

Get medical attention.
Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks : Harmful if inhaled.
May cause damage to organs through prolonged or repeated exposure.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
7.0	24.03.2025	1228554-00023	Date of first issue: 18.01.2017

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g. by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Soak up with inert absorbent material.
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling : Do not breathe mist or vapours.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment,

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Abamectin Liquid Formulation

Version 7.0 Revision Date: 24.03.2025 SDS Number: 1228554-00023 Date of last issue: 28.09.2024
Date of first issue: 18.01.2017

appropriate degowning and decontamination procedures,
industrial hygiene monitoring, medical surveillance and the
use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers : Keep in properly labelled containers. Keep tightly closed.
Keep in a cool, well-ventilated place. Store in accordance with
the particular national regulations.

Advice on common storage : Do not store with the following product types:
Strong oxidizing agents
Self-reactive substances and mixtures
Organic peroxides
Explosives
Gases

7.3 Specific end use(s)

Specific use(s) : No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
abamectin (combination of avermectin B1a and avermectin B1b) (ISO)	71751-41-2	TWA	15 µg/m ³ (OEB 3)	Internal
		Wipe limit	150 µg/100 cm ²	Internal

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006

Substance name	End Use	Exposure routes	Potential health effects	Value
Glycerides, mixed decanoyl and octanoyl	Workers	Inhalation	Long-term systemic effects	177,79 mg/m ³
	Workers	Skin contact	Long-term systemic effects	25,21 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	43,84 mg/m ³
	Consumers	Skin contact	Long-term systemic effects	12,61 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	12,61 mg/kg bw/day

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006

Substance name	Environmental Compartment	Value
Glycerides, mixed decanoyl and	Oral (Secondary Poisoning)	0,03 mg/kg food

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
7.0	24.03.2025	1228554-00023	Date of first issue: 18.01.2017

|| octanoyl

8.2 Exposure controls

Engineering measures

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

Personal protective equipment

Eye/face protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Hand protection	:	
Material	:	Chemical-resistant gloves
Remarks	:	Consider double gloving.
Skin and body protection	:	Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Respiratory protection	:	If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. Filter should conform to NS EN 14387
Filter type	:	Combined particulates and organic vapour type (A-P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state	:	liquid
Colour	:	light yellow
Odour	:	characteristic
Odour Threshold	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
7.0	24.03.2025	1228554-00023	Date of first issue: 18.01.2017

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Flash point : No data available

Auto-ignition temperature : No data available

Decomposition temperature : No data available

pH : No data available

Viscosity
Viscosity, kinematic : No data available

Solubility(ies)
Water solubility : insoluble

Partition coefficient: n-octanol/water : Not applicable

Vapour pressure : No data available

Relative density : No data available

Density : 0,90 - 0,94 g/cm³

Relative vapour density : No data available

Particle characteristics
Particle size : Not applicable

9.2 Other information

Explosives : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : No data available

Molecular weight : No data available

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
7.0	24.03.2025	1228554-00023	Date of first issue: 18.01.2017

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : None known.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

|| Harmful if inhaled.

Product:

Acute oral toxicity : Acute toxicity estimate: > 2.000 mg/kg
Method: Calculation method

Acute inhalation toxicity : Acute toxicity estimate: 2,3 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Method: Calculation method

Acute dermal toxicity : Acute toxicity estimate: > 2.000 mg/kg
Method: Calculation method

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

|| Acute oral toxicity : LD50 (Rat): 24 mg/kg
LD50 (Mouse): 10 mg/kg

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
7.0	24.03.2025	1228554-00023	Date of first issue: 18.01.2017

	LDLo (Monkey): 24 mg/kg
	Symptoms: Dilatation of the pupil
Acute inhalation toxicity	: LC50 (Rat): 0,023 mg/l
	Exposure time: 4 h
	Test atmosphere: dust/mist
Acute dermal toxicity	: LD50 (Rat): 330 mg/kg
	LD50 (Rabbit): 2.000 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species	: Rabbit
Result	: No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species	: Rabbit
Result	: Mild eye irritation

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Test Type	: Maximisation Test
Exposure routes	: Skin contact
Result	: Not a skin sensitizer.

Germ cell mutagenicity

Not classified based on available information.

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES)
-----------------------	--

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
7.0	24.03.2025	1228554-00023	Date of first issue: 18.01.2017

Genotoxicity in vivo	Result: negative
	Test Type: In vitro mammalian cell gene mutation test
	Test system: Chinese hamster lung cells
	Result: negative
	Test Type: Alkaline elution assay
	Result: negative
	Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
	Species: Mouse
	Application Route: Intraperitoneal injection
	Result: negative

Carcinogenicity

Not classified based on available information.

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species	: Rat
Application Route	: Oral
Exposure time	: 105 weeks
Result	: negative

Species	: Mouse
Application Route	: Oral
Exposure time	: 93 weeks
Result	: negative

Reproductive toxicity

Not classified based on available information.

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Effects on fertility	Test Type: Fertility
	Species: Rat, male
	Application Route: Oral
	Result: Effects on fertility
	Test Type: Two-generation reproduction toxicity study
	Species: Rat
	Application Route: Oral
	Early Embryonic Development: NOAEL: 0,12 mg/kg body weight
	Result: Fetotoxicity
Effects on foetal development	Test Type: Embryo-foetal development
	Species: Mouse
	Application Route: Oral

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
7.0	24.03.2025	1228554-00023	Date of first issue: 18.01.2017

	General Toxicity Maternal: NOAEL: 0,05 mg/kg body weight Developmental Toxicity: NOAEL: 0,2 mg/kg body weight Result: Cleft palate Remarks: Adverse developmental effects were observed
	Test Type: Embryo-foetal development Species: Rabbit Application Route: Oral Developmental Toxicity: LOAEL: 2 mg/kg body weight Result: Cleft palate, Teratogenic effects, Reduced embryonic survival Remarks: Adverse developmental effects were observed
	Test Type: Development Species: Rat Application Route: Oral Developmental Toxicity: LOAEL: 1,6 mg/kg body weight Result: Teratogenic effects
Reproductive toxicity - Assessment	: Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of adverse effects on development, based on animal experiments.

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Exposure routes	: Ingestion
Target Organs	: Central nervous system
Assessment	: Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Species	: Rat
NOAEL	: 1,5 mg/kg
Application Route	: Oral
Exposure time	: 24 Months
Target Organs	: Central nervous system
Symptoms	: Tremors, ataxia

Species	: Mouse
NOAEL	: 4,0 mg/kg
Application Route	: Oral

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
7.0	24.03.2025	1228554-00023	Date of first issue: 18.01.2017

Exposure time	: 24 Months
Target Organs	: Central nervous system
Symptoms	: Tremors, ataxia

Species	: Dog
NOAEL	: 0,25 mg/kg
LOAEL	: 0,5 mg/kg
Application Route	: Oral
Exposure time	: 53 Weeks
Target Organs	: Central nervous system
Symptoms	: Tremors, weight loss
Remarks	: mortality observed

Species	: Monkey
NOAEL	: 1,0 mg/kg
Application Route	: Oral
Exposure time	: 14 Weeks
Target Organs	: Central nervous system

Aspiration toxicity

Not classified based on available information.

11.2 Information on other hazards

Endocrine disrupting properties

Not classified based on available information.

Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Experience with human exposure

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Ingestion	: Symptoms: May cause, Tremors, Diarrhoea, central nervous system effects, Salivation, tearing
-----------	--

SECTION 12: Ecological information

12.1 Toxicity

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Toxicity to fish	: LC50 (Oncorhynchus mykiss (rainbow trout)): 3,2 µg/l Exposure time: 96 h
------------------	---

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
7.0	24.03.2025	1228554-00023	Date of first issue: 18.01.2017

	LC50 (Lepomis macrochirus (Bluegill sunfish)): 9,6 µg/l Exposure time: 96 h
	LC50 (Ictalurus punctatus (channel catfish)): 24 µg/l Exposure time: 96 h
	LC50 (Cyprinus carpio (Carp)): 42 µg/l Exposure time: 96 h
	LC50 (Cyprinodon variegatus (sheepshead minnow)): 15 µg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Americamysis): 0,022 µg/l Exposure time: 96 h
	EC50 (Daphnia magna (Water flea)): 0,34 µg/l Exposure time: 48 h
Toxicity to algae/aquatic plants	: EC50 (Pseudokirchneriella subcapitata (green algae)): 100 mg/l Exposure time: 72 h
M-Factor (Acute aquatic toxicity)	: 10.000
Toxicity to microorganisms	: EC50 : > 1.000 mg/l Exposure time: 3 h Test Type: Respiration inhibition
Toxicity to fish (Chronic toxicity)	: NOEC: 0,52 µg/l Exposure time: 32 d Species: Pimephales promelas (fathead minnow)
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	: NOEC: 0,03 µg/l Exposure time: 21 d Species: Daphnia magna (Water flea)
	NOEC: 0,0035 µg/l Exposure time: 28 d Species: Mysidopsis bahia (opossum shrimp)
M-Factor (Chronic aquatic toxicity)	: 10.000

12.2 Persistence and degradability

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Stability in water	: Hydrolysis: 50 %(< 12 h)
--------------------	----------------------------

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
7.0	24.03.2025	1228554-00023	Date of first issue: 18.01.2017

12.3 Bioaccumulative potential

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Bioaccumulation : Bioconcentration factor (BCF): 52

Partition coefficient: n-octanol/water : log Pow: 4

12.4 Mobility in soil

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Distribution among environmental compartments : log Koc: > 3,6

12.5 Results of PBT and vPvB assessment

Product:

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Endocrine disrupting properties

Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

12.7 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product	: Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.
Contaminated packaging	: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
7.0	24.03.2025	1228554-00023	Date of first issue: 18.01.2017

SECTION 14: Transport information

14.1 UN number or ID number

ADN	:	UN 3082
ADR	:	UN 3082
RID	:	UN 3082
IMDG	:	UN 3082
IATA	:	UN 3082

14.2 UN proper shipping name

ADN	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (abamectin (combination of avermectin B1a and avermectin B1b) (ISO))
ADR	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (abamectin (combination of avermectin B1a and avermectin B1b) (ISO))
RID	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (abamectin (combination of avermectin B1a and avermectin B1b) (ISO))
IMDG	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (abamectin (combination of avermectin B1a and avermectin B1b) (ISO))
IATA	:	Environmentally hazardous substance, liquid, n.o.s. (abamectin (combination of avermectin B1a and avermectin B1b) (ISO))

14.3 Transport hazard class(es)

	Class	Subsidiary risks
ADN	:	9
ADR	:	9
RID	:	9
IMDG	:	9
IATA	:	9

14.4 Packing group

ADN	:	
Packing group	:	III
Classification Code	:	M6
Hazard Identification Number	:	90
Labels	:	9

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
7.0	24.03.2025	1228554-00023	Date of first issue: 18.01.2017

ADR

Packing group	: III
Classification Code	: M6
Hazard Identification Number	: 90
Labels	: 9
Tunnel restriction code	: (-)

RID

Packing group	: III
Classification Code	: M6
Hazard Identification Number	: 90
Labels	: 9

IMDG

Packing group	: III
Labels	: 9
EmS Code	: F-A, S-F

IATA (Cargo)

Packing instruction (cargo aircraft)	: 964
Packing instruction (LQ)	: Y964
Packing group	: III
Labels	: Miscellaneous

IATA (Passenger)

Packing instruction (passenger aircraft)	: 964
Packing instruction (LQ)	: Y964
Packing group	: III
Labels	: Miscellaneous

14.5 Environmental hazards

ADN

Environmentally hazardous	: yes
---------------------------	-------

ADR

Environmentally hazardous	: yes
---------------------------	-------

RID

Environmentally hazardous	: yes
---------------------------	-------

IMDG

Marine pollutant	: yes
------------------	-------

IATA (Passenger)

Environmentally hazardous	: yes
---------------------------	-------

IATA (Cargo)

Environmentally hazardous	: yes
---------------------------	-------

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
7.0	24.03.2025	1228554-00023	Date of first issue: 18.01.2017

14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII) : Conditions of restriction for the following entries should be considered:
Number on list 3

Number on list 75: If you intend to use this product as tattoo ink, please contact your vendor.

Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the conditions in corresponding Regulation to determine whether an entry is applicable to the placing on the market or not.

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59) : Not applicable

REACH - List of substances subject to authorisation (Annex XIV) : Not applicable

Regulation (EU) No 2024/590 on substances that deplete the ozone layer : Not applicable

Regulation (EU) 2019/1021 on persistent organic pollutants (recast) : Not applicable

Regulation (EU) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals : abamectin (combination of avermectin B1a and avermectin B1b) (ISO)

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

E1

ENVIRONMENTAL
HAZARDS

Quantity 1
100 t

Quantity 2
200 t

Other regulations:

Note the regulation on organization, leadership and participation, chapter 12 on the work of children and young people.

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
7.0	24.03.2025	1228554-00023	Date of first issue: 18.01.2017

IECSC : not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements

H300	: Fatal if swallowed.
H311	: Toxic in contact with skin.
H330	: Fatal if inhaled.
H361fd	: Suspected of damaging fertility. Suspected of damaging the unborn child.
H372	: Causes damage to organs through prolonged or repeated exposure if swallowed.
H400	: Very toxic to aquatic life.
H410	: Very toxic to aquatic life with long lasting effects.

Full text of other abbreviations

Acute Tox.	: Acute toxicity
Aquatic Acute	: Short-term (acute) aquatic hazard
Aquatic Chronic	: Long-term (chronic) aquatic hazard
Repr.	: Reproductive toxicity
STOT RE	: Specific target organ toxicity - repeated exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic sub-

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Abamectin Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
7.0	24.03.2025	1228554-00023	Date of first issue: 18.01.2017

stance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Classification of the mixture:

Acute Tox. 4	H332
STOT RE 2	H373
Aquatic Acute 1	H400
Aquatic Chronic 1	H410

Classification procedure:

Calculation method
Calculation method
Calculation method
Calculation method

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NO / EN